172 related articles for article (PubMed ID: 38113463)
1. ZAP-70 augments tonic B-cell receptor and CCR7 signaling in IGHV-unmutated chronic lymphocytic leukemia.
Chen J; Sathiaseelan V; Reddy Chilamakuri CS; Roamio Franklin VN; Jakwerth CA; D'Santos C; Ringshausen I
Blood Adv; 2024 Mar; 8(5):1167-1178. PubMed ID: 38113463
[TBL] [Abstract][Full Text] [Related]
2. ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation.
Calpe E; Codony C; Baptista MJ; Abrisqueta P; Carpio C; Purroy N; Bosch F; Crespo M
Blood; 2011 Oct; 118(16):4401-10. PubMed ID: 21865343
[TBL] [Abstract][Full Text] [Related]
3. Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia.
Cuesta-Mateos C; López-Giral S; Alfonso-Pérez M; de Soria VG; Loscertales J; Guasch-Vidal S; Beltrán AE; Zapata JM; Muñoz-Calleja C
Exp Hematol; 2010 Sep; 38(9):756-64, 764.e1-4. PubMed ID: 20488224
[TBL] [Abstract][Full Text] [Related]
4. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL).
Richardson SJ; Matthews C; Catherwood MA; Alexander HD; Carey BS; Farrugia J; Gardiner A; Mould S; Oscier D; Copplestone JA; Prentice AG
Blood; 2006 May; 107(9):3584-92. PubMed ID: 16332969
[TBL] [Abstract][Full Text] [Related]
5. Differential gene expression profile associated to apoptosis induced by dexamethasone in CLL cells according to IGHV/ZAP-70 status.
Baptista MJ; Muntañola A; Calpe E; Abrisqueta P; Salamero O; Fernández E; Codony C; Giné E; Kalko SG; Crespo M; Bosch F
Clin Cancer Res; 2012 Nov; 18(21):5924-33. PubMed ID: 22966019
[TBL] [Abstract][Full Text] [Related]
6. T-cell independent, B-cell receptor-mediated induction of telomerase activity differs among IGHV mutation-based subgroups of chronic lymphocytic leukemia patients.
Damle RN; Temburni S; Banapour T; Paul S; Mongini PK; Allen SL; Kolitz JE; Rai KR; Chiorazzi N
Blood; 2012 Sep; 120(12):2438-49. PubMed ID: 22875913
[TBL] [Abstract][Full Text] [Related]
7. ZAP-70 constitutively regulates gene expression and protein synthesis in chronic lymphocytic leukemia.
Chen J; Sathiaseelan V; Moore A; Tan S; Chilamakuri CSR; Roamio Franklin VN; Shahsavari A; Jakwerth CA; Hake SB; Warren AJ; Mohorianu I; D'Santos C; Ringshausen I
Blood; 2021 Jul; 137(26):3629-3640. PubMed ID: 33619528
[TBL] [Abstract][Full Text] [Related]
8. Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis.
Del Giudice I; Chiaretti S; Santangelo S; Tavolaro S; Peragine N; Marinelli M; Ilari C; Raponi S; Messina M; Nanni M; Mauro FR; Piciocchi A; Bontempi K; Rossi D; Gaidano G; Guarini A; Foà R
Am J Hematol; 2014 Jan; 89(1):74-82. PubMed ID: 24030933
[TBL] [Abstract][Full Text] [Related]
9. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.
Chen L; Widhopf G; Huynh L; Rassenti L; Rai KR; Weiss A; Kipps TJ
Blood; 2002 Dec; 100(13):4609-14. PubMed ID: 12393534
[TBL] [Abstract][Full Text] [Related]
10. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.
Petlickovski A; Laurenti L; Li X; Marietti S; Chiusolo P; Sica S; Leone G; Efremov DG
Blood; 2005 Jun; 105(12):4820-7. PubMed ID: 15728130
[TBL] [Abstract][Full Text] [Related]
11. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
Wiestner A; Rosenwald A; Barry TS; Wright G; Davis RE; Henrickson SE; Zhao H; Ibbotson RE; Orchard JA; Davis Z; Stetler-Stevenson M; Raffeld M; Arthur DC; Marti GE; Wilson WH; Hamblin TJ; Oscier DG; Staudt LM
Blood; 2003 Jun; 101(12):4944-51. PubMed ID: 12595313
[TBL] [Abstract][Full Text] [Related]
12. Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells.
Rigoni M; Riganti C; Vitale C; Griggio V; Campia I; Robino M; Foglietta M; Castella B; Sciancalepore P; Buondonno I; Drandi D; Ladetto M; Boccadoro M; Massaia M; Coscia M
Oncotarget; 2015 Oct; 6(30):29833-46. PubMed ID: 26284584
[TBL] [Abstract][Full Text] [Related]
13. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.
Rassenti LZ; Huynh L; Toy TL; Chen L; Keating MJ; Gribben JG; Neuberg DS; Flinn IW; Rai KR; Byrd JC; Kay NE; Greaves A; Weiss A; Kipps TJ
N Engl J Med; 2004 Aug; 351(9):893-901. PubMed ID: 15329427
[TBL] [Abstract][Full Text] [Related]
14. FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia.
Li FJ; Ding S; Pan J; Shakhmatov MA; Kashentseva E; Wu J; Li Y; Soong SJ; Chiorazzi N; Davis RS
Blood; 2008 Jul; 112(1):179-87. PubMed ID: 18314442
[TBL] [Abstract][Full Text] [Related]
15. The
Perez-Chacon G; Zapata JM
Front Immunol; 2021; 12():627602. PubMed ID: 33912159
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling.
Dielschneider RF; Xiao W; Yoon JY; Noh E; Banerji V; Li H; Marshall AJ; Johnston JB; Gibson SB
Cell Death Dis; 2014 Oct; 5(10):e1439. PubMed ID: 25275600
[TBL] [Abstract][Full Text] [Related]
17.
Maity PC; Bilal M; Koning MT; Young M; van Bergen CAM; Renna V; Nicolò A; Datta M; Gentner-Göbel E; Barendse RS; Somers SF; de Groen RAL; Vermaat JSP; Steinbrecher D; Schneider C; Tausch E; Bittolo T; Bomben R; Mazzarello AN; Del Poeta G; Kroes WGM; van Wezel JT; Imkeller K; Busse CE; Degano M; Bakchoul T; Schulz AR; Mei H; Ghia P; Kotta K; Stamatopoulos K; Wardemann H; Zucchetto A; Chiorazzi N; Gattei V; Stilgenbauer S; Veelken H; Jumaa H
Proc Natl Acad Sci U S A; 2020 Feb; 117(8):4320-4327. PubMed ID: 32047037
[TBL] [Abstract][Full Text] [Related]
18. SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2.
von Wenserski L; Schultheiß C; Bolz S; Schliffke S; Simnica D; Willscher E; Gerull H; Wolters-Eisfeld G; Riecken K; Fehse B; Altfeld M; Nollau P; Binder M
Leukemia; 2021 Apr; 35(4):1073-1086. PubMed ID: 32826957
[TBL] [Abstract][Full Text] [Related]
19. CLL cells respond to B-Cell receptor stimulation with a microRNA/mRNA signature associated with MYC activation and cell cycle progression.
Pede V; Rombout A; Vermeire J; Naessens E; Mestdagh P; Robberecht N; Vanderstraeten H; Van Roy N; Vandesompele J; Speleman F; Philippé J; Verhasselt B
PLoS One; 2013; 8(4):e60275. PubMed ID: 23560086
[TBL] [Abstract][Full Text] [Related]
20. CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemia.
Perkins B; Showel M; Schoch L; Imus PH; Karantanos T; Yonescu R; Morsberger L; Ghiaur G; Gladstone DE; Jones RJ
Leuk Lymphoma; 2022 Jul; 63(7):1617-1623. PubMed ID: 35343368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
